TMDX Stock Overview
A commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
TransMedics Group, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$76.04 |
| 52 Week High | US$177.37 |
| 52 Week Low | US$67.77 |
| Beta | 2.07 |
| 11 Month Change | -39.25% |
| 3 Month Change | -55.32% |
| 1 Year Change | 8.10% |
| 33 Year Change | 247.06% |
| 5 Year Change | 305.55% |
| Change since IPO | 240.07% |
Recent News & Updates
These 4 Measures Indicate That TransMedics Group (NASDAQ:TMDX) Is Using Debt Reasonably Well
Nov 20
TransMedics: Long-Term Thesis Hasn't Changed At All
Nov 19TransMedics: Overreaction To Temporary Headwinds (Rating Upgrade)
Nov 12What You Can Learn From TransMedics Group, Inc.'s (NASDAQ:TMDX) P/S After Its 44% Share Price Crash
Oct 30TransMedics: Mistakes Have Been Made, Here's My Updated Outlook
Oct 29Recent updates
These 4 Measures Indicate That TransMedics Group (NASDAQ:TMDX) Is Using Debt Reasonably Well
Nov 20TransMedics: Long-Term Thesis Hasn't Changed At All
Nov 19TransMedics: Overreaction To Temporary Headwinds (Rating Upgrade)
Nov 12What You Can Learn From TransMedics Group, Inc.'s (NASDAQ:TMDX) P/S After Its 44% Share Price Crash
Oct 30TransMedics: Mistakes Have Been Made, Here's My Updated Outlook
Oct 29TransMedics' Organ Care: Critical Innovation With Lofty Expectations
Oct 23TransMedics Group: This Could Be One Of The Biggest Moats In A Decade
Oct 16Returns Are Gaining Momentum At TransMedics Group (NASDAQ:TMDX)
Sep 18TransMedics: Take Profits While The Valuation Is Sky High
Sep 18TransMedics: Wide Moat Player At A Lower Valuation Than Peers
Sep 10TransMedics Group, Inc.'s (NASDAQ:TMDX) P/S Is Still On The Mark Following 25% Share Price Bounce
Aug 28TransMedics: Heart And Lungs Will Drive The Next Leg Higher
Aug 19Analysts Just Made A Meaningful Upgrade To Their TransMedics Group, Inc. (NASDAQ:TMDX) Forecasts
Aug 06TransMedics Group: Providing Long-Term Detailed Forecast And Upgrading To Buy
Aug 04TransMedics Group, Inc. Just Recorded A 66% EPS Beat: Here's What Analysts Are Forecasting Next
Aug 02TransMedics Group Stock: Too Far, Too Fast
Jul 08TransMedics: NOP, Logistics And Transport Are Key Growth Drivers But Stock Is Pricey
Jun 17TransMedics Group (NASDAQ:TMDX) Might Have The Makings Of A Multi-Bagger
Jun 10TransMedics: Transportation Supporting Growth
May 21TransMedics Group: Looking At The Road Ahead After An Exceptional Q1 (Rating Downgrade)
May 06TransMedics Group, Inc. (NASDAQ:TMDX) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Apr 24TransMedics Group: Founder Led Company With Solid Potential
Apr 19Is TransMedics Group (NASDAQ:TMDX) Using Too Much Debt?
Apr 11TransMedics Group: Emerging Medical Device Market Leader With A Long Growth Runway
Mar 19TransMedics Group: Huge Opportunity In Organ Transplants
Mar 12TransMedics: A Very Expensive Growth Stock
Feb 07With TransMedics Group, Inc. (NASDAQ:TMDX) It Looks Like You'll Get What You Pay For
Jan 23Calculating The Fair Value Of TransMedics Group, Inc. (NASDAQ:TMDX)
Jan 02Does TransMedics Group (NASDAQ:TMDX) Have A Healthy Balance Sheet?
Nov 05This Just In: Analysts Are Boosting Their TransMedics Group, Inc. (NASDAQ:TMDX) Outlook for This Year
Aug 06TransMedics Group (NASDAQ:TMDX) Has Debt But No Earnings; Should You Worry?
Aug 02TransMedics Group, Inc. (NASDAQ:TMDX) Not Lagging Industry On Growth Or Pricing
Jun 29Brokers Are Upgrading Their Views On TransMedics Group, Inc. (NASDAQ:TMDX) With These New Forecasts
May 06Is TransMedics Group (NASDAQ:TMDX) Using Too Much Debt?
Apr 27Estimating The Intrinsic Value Of TransMedics Group, Inc. (NASDAQ:TMDX)
Apr 09Shareholder Returns
| TMDX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -5.5% | 1.5% | 2.2% |
| 1Y | 8.1% | 20.8% | 31.6% |
Return vs Industry: TMDX underperformed the US Medical Equipment industry which returned 20.9% over the past year.
Return vs Market: TMDX underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| TMDX volatility | |
|---|---|
| TMDX Average Weekly Movement | 11.4% |
| Medical Equipment Industry Average Movement | 8.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TMDX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TMDX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 584 | Waleed Hassanein | www.transmedics.com |
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers.
TransMedics Group, Inc. Fundamentals Summary
| TMDX fundamental statistics | |
|---|---|
| Market cap | US$2.55b |
| Earnings (TTM) | US$32.64m |
| Revenue (TTM) | US$401.09m |
78.2x
P/E Ratio6.4x
P/S RatioIs TMDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TMDX income statement (TTM) | |
|---|---|
| Revenue | US$401.09m |
| Cost of Revenue | US$163.10m |
| Gross Profit | US$237.99m |
| Other Expenses | US$205.35m |
| Earnings | US$32.64m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.97 |
| Gross Margin | 59.34% |
| Net Profit Margin | 8.14% |
| Debt/Equity Ratio | 242.2% |
How did TMDX perform over the long term?
See historical performance and comparison